Skip to main content
S&P 5007,615.85+0.40%DOW52,101.39+0.02%NASDAQ26,187.71+0.79%BTC$75,686.00-0.38%ETH$2,391.20-0.61%GOLD$4,390.20+1.32%OIL$102.99-2.68%
Smart Investors Daily
EP

NASDAQ · EPRX

Eupraxia Pharmaceuticals Inc.

Healthcare · Biotechnology

$8.11

Up+$0.04 (+0.50%)

Updated Sep 16, 2026, 12:07 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
216.11M
P/E ratio
-7.17
Dividend yield
0.00%
52-week range
$5.16 – $9.32
Volume
197.83K
Avg. volume
144.03K

Price performance

EPRX price history

1M range · 20 trading sessions · Daily adjusted prices

EPRX closed at $8.11 after 20 trading sessions, up 18.39% for the selected period.

Last close
$8.11
Period change
+18.39%
Period low
$6.34
Period high
$8.42
Daily close
View OHLC price history
EPRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$8.05$8.14$7.93$8.11197.83K
Sep 14, 2026$8.32$8.365$8.00$8.07432.12K
Sep 11, 2026$8.14$8.49$8.11$8.42492.93K
Sep 10, 2026$7.95$8.30$7.8402$8.02260.91K
Sep 9, 2026$8.18$8.33$8.00$8.08186.53K
Sep 8, 2026$8.42$8.60$8.22$8.25375.21K
Sep 4, 2026$7.45$8.40$7.39$8.403.52M
Sep 3, 2026$7.52$7.63$7.35$7.50401.9K
Sep 2, 2026$6.40$7.47$6.33$7.45749.99K
Sep 1, 2026$6.46$6.53$6.33$6.34151.66K
Aug 31, 2026$6.67$6.855$6.33$6.46370.7K
Aug 28, 2026$7.38$7.4474$6.665$6.675174.23K
Aug 27, 2026$7.42$7.53$7.30$7.36208.63K
Aug 26, 2026$7.37$7.47$7.24$7.43235.5K
Aug 25, 2026$7.31$7.46$7.13$7.42562.44K
Aug 24, 2026$6.75$7.38$6.64$7.281.36M
Aug 21, 2026$6.77$6.875$6.6788$6.73298.01K
Aug 20, 2026$6.97$7.04$6.69$6.76176.21K
Aug 19, 2026$6.93$7.0899$6.80$7.01395.5K
Aug 18, 2026$6.81$6.88$6.715$6.85379.17K

Latest EPRX news

The latest Smart Investors Daily articles mentioning EPRX.

Stock researchCompany · Overview

EPRX research

Overview

Company profile and research snapshot.

Company profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
EPRX recent ratings
DateFirmRatingTarget
May 21, 2026RAYMOND JAMES LTD.Strong Buy—
May 12, 2026WILLIAM BLAIR & COMPANYOutperform—
May 4, 2026LEEDE JONES GABLEBuy—
May 3, 2026RESEARCH CAPITAL CORPORATIONBuy—
Jan 8, 2026RESEARCH CAPITAL CORPORATIONBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced today that its common shares have commenced trading on the Nasdaq Global Select Market. The Company also announced that members of its management tea

Yahoo · Aug 13, 2026

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatmentIn the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and 52 weeks timepointsThe number of patients experiencing moderate to severe dysphagia (difficulty swallowing) in Cohorts 7-9 was reduced from 77% at baseline to

Benzinga · Aug 11, 2026

Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By